Arthralgias and myalgias related to quinupristin-dalfopristin administration.

K. M. Olsen, J. A. Rebuck, Mark Edmund Rupp

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

This study evaluated the frequency of and potential risk factors for arthralgias and/or myalgias associated with quinupristin-dalfopristin administration. Of 32 patients who received quinupristin-dalfopristin treatment, at least 15 (47%) developed arthralgias and/or myalgias. Clinicians should be aware of these adverse events associated with quinupristin-dalfopristin, which may occur more frequently than has been previously reported.

Original languageEnglish (US)
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume32
Issue number4
StatePublished - Jan 1 2001

Fingerprint

Myalgia
Arthralgia
quinupristin-dalfopristin
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{242323a88a954a1db982c9f2c660e914,
title = "Arthralgias and myalgias related to quinupristin-dalfopristin administration.",
abstract = "This study evaluated the frequency of and potential risk factors for arthralgias and/or myalgias associated with quinupristin-dalfopristin administration. Of 32 patients who received quinupristin-dalfopristin treatment, at least 15 (47{\%}) developed arthralgias and/or myalgias. Clinicians should be aware of these adverse events associated with quinupristin-dalfopristin, which may occur more frequently than has been previously reported.",
author = "Olsen, {K. M.} and Rebuck, {J. A.} and Rupp, {Mark Edmund}",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "32",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Arthralgias and myalgias related to quinupristin-dalfopristin administration.

AU - Olsen, K. M.

AU - Rebuck, J. A.

AU - Rupp, Mark Edmund

PY - 2001/1/1

Y1 - 2001/1/1

N2 - This study evaluated the frequency of and potential risk factors for arthralgias and/or myalgias associated with quinupristin-dalfopristin administration. Of 32 patients who received quinupristin-dalfopristin treatment, at least 15 (47%) developed arthralgias and/or myalgias. Clinicians should be aware of these adverse events associated with quinupristin-dalfopristin, which may occur more frequently than has been previously reported.

AB - This study evaluated the frequency of and potential risk factors for arthralgias and/or myalgias associated with quinupristin-dalfopristin administration. Of 32 patients who received quinupristin-dalfopristin treatment, at least 15 (47%) developed arthralgias and/or myalgias. Clinicians should be aware of these adverse events associated with quinupristin-dalfopristin, which may occur more frequently than has been previously reported.

UR - http://www.scopus.com/inward/record.url?scp=18044402924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044402924&partnerID=8YFLogxK

M3 - Article

VL - 32

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -